22nd Century Group (NYSE: XXII) is a plant biotechnology company focused on the development of technology that permits the management of nicotine levels in tobacco plants through genetic engineering and plant breeding. The company currently owns or exclusively controls more than 185 issued patents and more than 54 pending patent applications around the world. Through the development of innovative smoking cessation products and modified risk tobacco products, XXII aims to reduce the harm caused by conventional cigarettes. For more information, visit the company’s website at www.xxiicentury.com.